Don't miss the opportunity to discover the winning strategies to launch your pharmaceutical product in Europe. On November 7, Swiss HLG, in collaboration with Italy HLG and Pharma Licensing Club France, will host a free webinar with a particular focus on marketing strategies. One of the speeches, entitled "Challenges for New Market Entrants in Launching Their Product in Europe", will be held by Ronald Van Zitteren a logistics and supply chain expert with over 33 years of international experience, including 20 in the life sciences and healthcare sectors. Van Zitteren has held leadership roles in 6 multinational companies and has supported over 25 biopharmaceutical companies in optimizing their supply chains. Register now ➡https://lnkd.in/eDFu-J4G
Swiss HLG
Branchenverbände
Basel, Basel 1.814 Follower:innen
Welcome to Swiss HLG, more than networking
Info
We are a group of Healthcare Licensing Professionals working together to serve those actively involved in business development and licensing within the pharmaceutical, biotechnology and healthcare industry. As a professional association, we are run by a board elected by its members. Our Vision Building relationships for a better healthcare environment Our Mission Swiss HLG is an association of business development professionals, well recognized within the healthcare industry It provides a unique and inspiring environment for building relationships, sharing best practices and facilitating business interactions Our Values Trust and respect Passion Openness High Quality
- Website
-
www.swisshlg.com
Externer Link zu Swiss HLG
- Branche
- Branchenverbände
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Basel, Basel
- Art
- Nonprofit
- Gegründet
- 2002
- Spezialgebiete
- healthcare, pharmaceutic industry und business development
Orte
-
Primär
Wegbeschreibung
St.-Jakobs-Strasse 7
Postfach 2879
Basel, Basel 4200, CH
Beschäftigte von Swiss HLG
-
Francesca Lianza
Life Science | Business Development | Strategic Partnerships | Deal Making | Alliances | In and out-licensing | M&A | Innovation | Strategy |…
-
Sarah Holland
Chief Business Officer at Cureteq AG, building a compelling portfolio of differentiated assets driven by AI insights
-
Luis Vieira
Business Development Lead at Helsinn Group
-
Christian (Chris) Isler
Managing Principal EMEA Strategy Consulting | Member of the Board at Swiss HLG | ex-Pfizer
Updates
-
A few days ago, the Swiss HLG co-organized, along with Biopôle Lausanne and BioAlps - Swiss Health Valley, an engaging panel discussion on the topic “Negotiations: Aligning Stakeholders for Success”. 🤝 When it comes to dealmaking, stakeholder management is an essential component. With each stakeholder having different perspectives and interests, their alignment is key to achieving an agreement. In that context, we heard from experienced dealmakers from multiple backgrounds to gain a broad understanding of the deal process in biopharma. 🗣 Our talented speakers shared valuable insights: Raluca Flükiger, Ph.D, CLP, Licensing Officer at University of Geneva/UNITEC Vincent Ossipow, Partner at Omega Funds Sergio Capancioni, Director of Search & Evaluation at AbbVie Madiha Derouazi, CSO at AC Immune Some of the key takeaways included: ▪️ Robust licensing agreements between universities and spin-out companies are critical for downstream conversations (future fundraising, sub-licensing, eventual M&A). ▪️ Each pharma partner has a different process: make sure you inquire about it during your partnering conversations, and do not hesitate to engage early to ask for feedback. ▪️ Adequate incentives for management and selected employees are key for successful alignment with investors during an exit. The panel discussion, which included Q&A from the audience, was followed by a networking apero during which all the attendees could exchange ideas. #swisshlg #networking #Romandie #dealmaking #dealmakers #partnering #pharma #fundraising
-
-
📌Join our free Swiss HLG, Pharma Licensing Club France & Italy HLG timely webinar on the 7th November from 14:30 -16:00 CET. STRATEGIC COMMERCIALIZATION OPTIONS IN EUROPE FOR MID SIZED HEALTHCARE COMPANIES 📣 Ronald Van Zitteren, Principal at AIM will discuss the challenges faced by New Market Entrants in launching their products in Europe and Francois-Xavier CAPELO, VP International, Bioprojet will talk about Bioprojet’s orphan drug launch in Europe. These two sessions will be followed by a live Q&A moderated by Bruno Delie, General Manager, Luye Pharma EU. 👉Register here ➡https://lnkd.in/eDFu-J4G #swisshlg #healthcare #commercialisation #newmarket #pharmaproducts #webinar
-
-
Our Romandie networking event on Oct 3 in collaboration with Biopôle Lausanneand BioAlps - Swiss Health Valley was a great success! Around 50 attendees enjoyed an insightful and stimulating discussion on the topic of Negotiations: Aligning Stakeholders for Success. Read Pierre-Jean's excellent summary below: #swisshlg #dealmaking #networking #innovation #biopharma
𝗡𝗲𝗴𝗼𝘁𝗶𝗮𝘁𝗶𝗼𝗻𝘀: 𝗔𝗹𝗶𝗴𝗻𝗶𝗻𝗴 𝗦𝘁𝗮𝗸𝗲𝗵𝗼𝗹𝗱𝗲𝗿𝘀 𝗳𝗼𝗿 𝗦𝘂𝗰𝗰𝗲𝘀𝘀 Last week, I had the pleasure of co-organizing an insightful event with Swiss HLG and BioAlps - Life Sciences Cluster 🇨🇭 , where we explored the critical role of negotiations in startup success. We were honored to have four experts share their invaluable experiences on how seamless collaboration between 𝗧𝗲𝗰𝗵 𝗧𝗿𝗮𝗻𝘀𝗳𝗲𝗿 𝗢𝗳𝗳𝗶𝗰𝗲𝘀 (TTOs), 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀, and 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗽𝗹𝗮𝘆𝗲𝗿𝘀 is essential from a 𝘀𝘁𝗮𝗿𝘁𝘂𝗽’s inception to its exit. What stood out was how the negotiation process involves far more stakeholders than we typically imagine. Raluca Flükiger, Ph.D, CLP Flückiger, Licensing Officer at Université de Genève/UNITEC, emphasized the delicate balance that TTOs must strike—not only with entrepreneurs but also with internal departments like research, legal, and administration. Their challenge? Navigating high uncertainty while ensuring fair returns in case of success. From the investor’s perspective, Vincent Ossipow, Partner at Omega Funds, highlighted how crucial it is for investors, management, and employees to align—especially when exit values fall below expectations. In these cases, preferential rights might benefit investors exclusively. Sergio Capancioni, Director of Search & Evaluation at AbbVie, pointed out the importance of internal alignment to maintain interest and momentum when a promising lead is identified. Madiha Derouazi, a serial entrepreneur, offered a comprehensive 360° view of how to balance the intricate relationships between employees, management, boards, and investors, as well as the TTO-investor-acquirer dynamic. She underscored the need for professionals with deep process knowledge to foster a frictionless alignment of all parties involved. In your experience, which stakeholders have been most crucial to your success?
-
-
Swiss HLG, Pharma Licensing Club France & Italy HLG invites you to join us for this timely webinar on the 7th November from 14:30 -16:00 CET. STRATEGIC COMMERCIALIZATION OPTIONS IN EUROPE FOR MID SIZED HEALTHCARE COMPANIES Ronald Van Zitteren, Principal at AIM will discuss the challenges faced by New Market Entrants in launching their products in Europe and Francois-Francois-Xavier CAPELO, VP International, Bioprojet will talk about Bioprojet’s orphan drug launch in Europe. These two sessions will be followed by a live Q&A moderated by Bruno Delie, General Manager, Luye Pharma EU. 👉Register here ➡https://lnkd.in/eDFu-J4G #swisshlg #healthcare #commercialisation #newmarket #pharmaproducts #webinar #orphandrug #launch #biopharma #dealmaking #innovation #networking
-
-
If you are attending the Sachs Associates meeting in Basel this week, don't miss the biopharma dealmaking panel chaired by Swiss HLG President Sarah Holland first thing on Thursday morning. With a strong line-up of panelists, this promises to be a very insightful discussion on latest deal trends. #swisshlg #networking #biopharma #dealmaking #innovation #healthcare
💼🔬 Stay Ahead in Bio-Pharma Dealmaking! Join us for the 'Latest Trends in Dealmaking for Bio-Pharma Panel' at the #Sachs_BEF on September 26th, 2024, at the Mövenpick Hotel Basel. Discover the strategies driving successful partnerships and transactions in the biopharmaceutical sector. Chaired by: Sarah Holland, President of Swiss HLG & CBO, Cureteq AG - a Partex Company Panellists: Alessandra Polara, Senior Director, Global BD, F. Hoffmann-La Roche AG Berthold Hinzen, Global Head BD&L Transactions Immunology, Novartis AG Jeremy Griggs, Executive Director, Search & Evaluation, GSK Richard Ward, Executive Director, Search & Evaluation, AstraZeneca Sandra von Meier, Head Business Development & Licensing, Debiopharm International SA This panel offers a deep dive into the evolving landscape of dealmaking in the biopharma industry. Learn from top executives and dealmakers as they explore the latest trends, strategies, and challenges in mergers, acquisitions, and strategic partnerships. Gain insights into how these dynamics are shaping the industry and what it means for future innovation and growth. Don’t miss this chance to enhance your strategic decision-making and networking capabilities. Secure your spot today at www.sachsforum.com/24bef and join us, both #inperson & #online, during the Sachs Autumn Life Sciences Week. #BioPharmaDeals #PharmaMergers #StrategicPartnerships #Biotech #PharmaIndustry #Sachs_BEF #SALSW
-
-
If you are attending the Sachs Associates conference in Basel this week, do come along to the panel on AI chaired by Swiss HLG President Sarah Holland tomorrow morning. It promises to be a lively discussion of the real impact of AI on biopharma R&D and dealmaking. #swisshlg #networking #AI #innovation #biopharma #healthcare
🧬🤖 Discover the Real Impact of AI in Biopharma! Join us for the 'AI Transforming BioPharma Panel: Beyond the Hype' at the #Sachs_BEF on September 25th, 2024, at the Mövenpick Hotel Basel. Explore the genuine advancements and practical applications of artificial intelligence that are revolutionizing biopharmaceuticals. Chaired by: Sarah Holland, President of Swiss HLG & CBO, Cureteq AG - a Partex Company Panellists: Frank Grams, Chief Commercial Officer, Partex N.V. Katharina Kreymborg, SVP, Curie.Bio Parker Moss, EVP Corporate Development, Exscientia Patrick Schwab, Senior Director, AI & Machine Learning, GSK Ricardo Gaminha Pacheco, Strategic Partnering, BD&L Director, Insilico Medicine This panel will cut through the noise to examine how AI technologies are truly transforming drug discovery, development, and market strategies. Engage with industry experts as they discuss overcoming challenges, achieving breakthroughs, and forecasting the future of AI in biopharma. Don’t miss this opportunity to gain in-depth insights and network with pioneers in the field. Secure your spot today at www.sachsforum.com/24bef and join us, both #InPerson & #Online, during the Sachs Autumn Life Sciences Week. #ArtificialIntelligence #Biopharma #DrugDiscovery #BiotechInnovation #PharmaTech #LifeSciences #SALSW
-
-
Hurry, less than a month to go! Join us for our annual after work networking event in Swiss Romandie in collaboration with Biopôle Lausanne and BioAlps - Swiss Health Valley on October 3rd at Biopôle in Lausanne. 🗣️There will be a panel discussion with speakers: Raluca Flükiger, Ph.D, CLP , Vincent Ossipow, Sergio Capancioni and Madiha Derouazi on the theme “Negotiations: Aligning stakeholders to success” with representatives from start-up, academia, pharma and venture capital. The panel will be followed by a networking apero. 👉Register here ➡https://lnkd.in/eHiJuaFb We look forward to seeing you there!
-
-
Congratulations to HAYA Therapeutics on this exciting news. It is fantastic to see a company that participated in our start-up initiative announce a great partnership. #swisshlg #innovation #partnering #dealmaking #healthcare
We are thrilled to announce a multi-year collaboration with Eli Lilly and Company to discover novel regulatory genome targets for obesity & related metabolic conditions. The total deal aggregates $1 billion in pre-clinical, clinical and commercial milestone payments, as well as royalties on product sales. "This partnership with Lilly demonstrates the significant advances we have made with our revolutionary regulatory genome RNA-guided platform and validates the potential of targeting lncRNA for chronic conditions. We look forward to working closely with Lilly, an established leader in developing treatments for metabolic diseases, to help bring patients novel disease-modifying therapeutics that could offer greater efficacy, safety and accessibility than currently available treatments" – Samir Ounzain Co-Founder and CEO. Read more about this collaboration in our latest Press Release: https://lnkd.in/eGDSiHHd #Collaboration #Obesity #MetabolicConditions #lncRNA #RegulatoryGenome #HAYATherapeutics
-
-
Join us for our annual after work networking event in Swiss Romandie in collaboration with Biopôle Lausanne and BioAlps - Swiss Health Valley on October 3rd at Biopôle in Lausanne. 🗣️There will be a panel discussion with speakers: Raluca Flükiger, Vincent Ossipow, Sergio Capancioni and Madiha Derouazi on the theme “Negotiations: Aligning stakeholders to success” with representatives from start-up, academia, pharma and venture capital. The panel will be followed by a networking apero. 👉Register here ➡https://lnkd.in/eHiJuaFb We look forward to seeing you there!
-